While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to ...

The MIT professor of management, who already sits on the CDC's revamped immunization advisory committee, is a known skeptic ...

Based on new data, argenx expects to file for the expansion of Vyvgart’s label into patients with generalized myasthenia ...

The White House has denied reports that the government could soon ban COVID-19 vaccines, noting that in the absence of an ...

Appia Bio's shutdown continues an unfortunate trend this year that has seen biotech closures nearly every month.

Closely watched data from Eli Lilly and Viking Therapeutics this month have reignited the discussion around oral weight-loss ...

Companies have claimed improvements to yield, batch consistency and output while acknowledging the risks and challenges ...

The biotech sector has not seen an IPO in six months. The market has remained frozen amid broader macro pressures and the ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

Thousands of employees across the Department of Health and Human Services are set to lose their collective bargaining rights ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

The FDA Adverse Event Reporting System, which Commissioner Marty Makary called “clunky,” previously published updates on a ...